Vaxxel

Villeurbanne, France

Vaxxel is an Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections

$1.3M raised

Mar 2022

Seed

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Vaxxel raised?

Vaxxel has raised $1.3M in total funding. The most recent round was Seed. The last funding was announced in March 2022.

Who are Vaxxel's investors?

Vaxxel's investors include Bpifrance, Femmes Business Angels, Angels Santé.

Where is Vaxxel headquartered?

Vaxxel is headquartered in Villeurbanne, France.

What does Vaxxel do?

Vaxxel is an Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections

What stage is Vaxxel at?

Vaxxel is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 18, 2022.

MLA

"Vaxxel — Funding & Investors." VCBacked, March 18, 2022, https://www.vcbacked.co/company/vaxxel. Accessed July 1, 2026.

APA

VCBacked. (2022). Vaxxel — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/vaxxel

Wikipedia (cite web)

{{cite web |title=Vaxxel — Funding & Investors |url=https://www.vcbacked.co/company/vaxxel |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 18, 2022.